ERIKA SHEPARD: Open Payments
NPI 1881132140 · BRIGHTON, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$251 in 14 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $148 · 2025 $251
Food & beverage: $251
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $37 |
| ABBVIE INC. | 2 | $35 |
| Novo Nordisk Inc | 2 | $33 |
| IBSA Pharma Inc. | 2 | $33 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Seqirus USA Inc | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Amgen Inc. | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $20 |
Products named: MOUNJARO, UBRELVY, Wegovy, Tirosint, Fluad, GARDASIL 9, OTEZLA, SHINGRIX.
Industry payments across CO — which companies pay providers there.
